VITAMIN D METABOLITES AS BIOMARKERS FOR THE IDENTIFICATION OF KIDNEY INJURY IN CARDIAC SURGERY

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how vitamin D metabolites in the blood can help identify kidney injuries in patients who are having heart surgery. The researchers want to see if the levels of these vitamin D substances relate to kidney function, which they will measure using a blood test called serum creatinine. They will involve 60 patients in total, divided into three groups based on their kidney function: those with normal kidney function, those with moderate impairment, and those with severe dysfunction.

To participate in this trial, you must be at least 18 years old and scheduled for cardiac surgery, with a serum creatinine test done within 28 days of the surgery. However, if you are taking certain medications for vitamin D, have had surgery on your parathyroid glands, or have specific liver or kidney diseases, you may not be eligible. Participants will simply need to provide blood samples for the study, and this research aims to improve the understanding of how to detect kidney injuries during heart surgery, which could lead to better care in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • ≥ 18 years
• • Patients undergoing cardiac surgery
• • Serum Creatinine measured with 28 days of surgery
• • Exclusion Criteria
• • Exogeneous calcitriol (1,25(OH)2D3) intake
• • History of parathyroidectomy
• • Patients with liver or kidney cancer
• • Patients with liver disease (e.g. liver failure, cirrhosis)